Skip to main content

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • USFDA issues 6 observations after inspection of Aurobindo Pharma Jedcherla plant

    Aurobindo Pharma receives 6 observations after inspection of Aurobindo Pharma Jedcherla plant.

    The United States Food and Drug Administration (US FDA) inspected Aurobindo Pharma's Unit VII, an oral manufacturing facility situated at Jedcherla, Hyderabad, from 2nd to 10th May 2022.

  • Sun Pharma Halol unit gets 10 observations under USFDA Form 483

    US FDA has conducted a Good Manufacturing Practices (GMP) inspection of Sun Pharmaceutical Industries Limited Halol facility Gujarat from April 26 to May 9, 2022. At the conclusion of the inspection, the US FDA issued a Form-483, with 10 observations.

  • Pfizer set up first drug development plant of Asia in Chennai

    US Pharma giant Pfizer has set up its global drug development centre at the Indian Institute of Technology-Madras Research Park with an investment of around 150 crore. This facility employs more than 250 scientists and professionals from a range of scientific disciplines, including Formulation Scientists and Pharmacists, Analytical Scientists, Life Science specialists such as Microbiologists and Biotechnologists, Chemical Engineers, Data Scientists and Program Managers.

  • HPCI Exhibition & Conference 2022

    HPCI (Home and Personal Care Ingredients) Exhibition and Conference was held in Mumbai at Sahara Star Hotel on 28th & 29th April 2022. Focus of this event is on raw materials, active ingredients and techniques for the formulation of cosmetic and home care products. The thrust was on the innovative ingredients for formulating effective cosmetic and home care products. It is the place to meet peers face-to-face, experience and discuss the latest developments and identify innovative products and solutions.

  • Future wearable health tech could measure gases released from skin

    Scientists have taken the first step to creating the next generation of wearable health monitors. Most research on measuring human biomarkers, which are measures of a body’s health, rely on electrical signals to sense the chemicals excreted in sweat. But sensors that rely on perspiration often require huge amounts of it just to get a reading.

  • A jump through time – new technique rewinds the age of skin cells by 30 years

    Research from the Babraham Institute has developed a method to ‘time jump’ human skin cells by 30 years, turning back the ageing clock for cells without losing their specialised function. Work by researchers in the Institute’s Epigenetics research programme has been able to partly restore the function of older cells, as well as rejuvenating the molecular measures of biological age. The research is published today in the journal eLife and whilst at an early stage of exploration, it could revolutionise regenerative medicine.

  • Unlocking a cure for carbon monoxide poisoning

    Carbon monoxide is an odorless and colorless gas made when fossil fuels burn incompletely. It’s also a silent killer.

    According to the Centers for Disease Control (CDC), more than 400 deaths and 20,000 ER visits can be attributed to carbon monoxide poisoning every year. The most common carbon monoxide (CO) poisoning symptoms are headache, dizziness, weakness, upset stomach, vomiting, chest pain, and confusion. Because it mimics the flu, people may experience symptoms without realizing the danger.

  • Biocon Biologics gets USD 90 mn contract from Malaysia to supply insulin

    Biocon Biologics Limited a subsidiary of Biocon Ltd announced that its subsidiary Biocon Sdn. Bhd. in Malaysia has been awarded a three-year contract, valued at USD 90 million* (MYR 375 million), for its recombinant human insulin brand Insugen®, by the Ministry of Health (MoH), Malaysia.

  • Moderna Files for Authorization of Its COVID-19 Vaccine in Young Children Six Months to Under Six Years of Age

    Moderna, Inc a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has submitted a request for emergency use authorization (EUA) for its COVID-19 vaccine (mRNA-1273) in children 6 months to under 2 years and 2 years to under 6 years of age to the U.S. Food and Drug Administration and that similar requests are underway with international regulatory authorities. The requests are based on a 25 μg two-dose primary series of mRNA-1273.

  • Aspirin Does Not Cut Risk in Non-Obstructive Coronary Artery Disease

    Aspirin therapy, as opposed to statin use, for non-obstructive coronary artery disease does not reduce major cardiovascular events, according to a new study published in the journal Radiology: Cardiothoracic Imaging.

Subscribe to Pharma News

Search this website